This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
- Conditions
- Carcinoma, Non-Small-Cell LungNeoplasms
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 172
- Registration Number
- NCT03156114
- Locations
- 🇪🇸
Hospital Universitari Dexeus, Barcelona, Spain
🇪🇸Hospital Politècnic La Fe, Valencia, Spain
🇬🇧Sarah Cannon Research Institute, London, United Kingdom
Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT03151499
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Drug: Rabeprazol sodium
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT03143166
- Locations
- 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan
BI 443651 Methacholine Challenge
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT03135899
- Locations
- 🇬🇧
The Medicines Evaluation Unit, Manchester, United Kingdom
Health-related Quality of Life in Patients on Anticoagulants
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 535
- Registration Number
- NCT03134911
- Locations
- 🇪🇸
Hospital Universitario Príncipe de Asturias, Alcalá De Henares (Madrid), Spain
🇪🇸Hospital Público Virgen de los Lirios, Alcoy (Alicante), Spain
🇪🇸Hospital San Juan de Dios, Bormujos (Sevilla), Spain
Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 59
- Registration Number
- NCT03135548
- Locations
- 🇨🇦
York Dermatology Clinic and Research Centre, Richmond Hill, Ontario, Canada
🇨🇦Innovaderm Research Inc., Montreal, Quebec, Canada
🇩🇰Gentofte Hospital, Hellerup, Denmark
A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT03123120
- Locations
- 🇩🇰
Aalborg Sygehus Syd, Aalborg, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
🇪🇸Hospital Puerta de Hierro, Majadahonda, Spain
Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects
- Conditions
- Healthy
- Interventions
- Drug: BI 705564 (Test)Drug: PlaceboDrug: BI 705564 (Reference)
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 91
- Registration Number
- NCT03123185
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT03123094
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
Safety and Tolerability of BI 685509 in Healthy Subjects
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT03116906
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany